Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis
Mayo Clinic researchers in Rochester, MN, seek ALS patients to participate in a trial exploring the safety and efficacy of a treatment involving the patient’s own (autologous) stem cells. The treatment will draw stem cells from the patient’s body fat and be multiplied in a lab before being injected into the patient’s spinal fluid through an intrathecal (spinal) injection.
The trial requires treatment every 3 months for a total of 4 intrathecal injections over 12 months.
- Be 18 years of age or older
- Have a diagnosis of ALS
- Must agree to 2 forms of birth control, if female
- Not have an autoimmune disorder, malignancy 5 years prior, or prior stem cell therapy of any kind
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- Mesenchymal stem cells will be drawn from the patient’s adipose, or fat, tissue.
- After the stem cells are amplified in the lab (over a period of weeks), the patient will return to receive a single dose of the stem cells via spinal injection 3 months for a total of 4 intrathecal injections over 12 months.
LOCATIONS AND CONTACTS:
The study site is at Mayo Clinic in Rochester, MN. Map.
Michelle M Turner | [email protected] | 507-284-2676
Carol Denny | [email protected] | 507-284-2676
Mayo Clinic & State of Minnesota Regenerative Medicine
Or go online: